Abstract
Cross-reactivity to SARS-CoV-2 from previous exposure to endemic coronaviruses (eHCoV) is gaining increasing attention as a possible driver of both protection against infection and severity of COVID-19 disease. Here, we use a stochastic individual-based model to show that heterogeneities in individual exposure histories to endemic coronaviruses are able to explain observed age patterns of hospitalisation due to COVID-19 in EU/EEA countries and the UK, provided there is (i) a decrease in cross-protection to SARS-CoV-2 with the number of eHCoV exposures and (ii) an increase in potential disease severity with number of eHCoV exposures or as a result of immune senescence. We also show that variation in health care capacity and testing efforts is compatible with country-specific differences in hospitalisation rates. Our findings call for further research on the role of cross-reactivity to endemic coronaviruses and highlight potential challenges arising from heterogeneous health care capacity and testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FP was funded by the UKRI GCRF One Health Poultry Hub (Grant No. BB/S011269/1), one of twelve interdisciplinary research hubs funded under the UK government’s Grand Challenge Research Fund Interdisciplinary Research Hub initiative. JL was supported by a Lectureship from the Department of Zoology, University of Oxford. SG acknowledges funding from the ERC UNIFLUVAC (812816) and MRC CiC 6 as well the Georg und Emily Von Opel Foundation. DSCD is funded by the grant 19/23343-7 and 2020/06160-3 from the Säo Paulo Research Foundation (FAPESP). MG is supported by Fundaçäo de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). LCJA acknowledges funding from PAHO (Pan American Health Organization) SCON2019-00572 (SCON2018-00572). UO and PW declare no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from The European Surveillance System - TESSy, provided by Austria, Croatia, Cyprus, Estonia, Finland, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, United Kingdom and released by ECDC.
